NCT02292173View on ClinicalTrials.gov

Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 18, 2015

Primary Completion Date

December 18, 2018

Study Completion Date

January 31, 2021

Conditions
Hepatocellular CancerLiver Cancer
Interventions
DRUG

Trametinib

"Dose Escalation:~Level 1: 1 mg daily. Level 2: 1.5 mg daily. Level 3: 1.5 mg daily. Level 4: 2 mg daily.~Dose Expansion:~Maximum Tolerated Dose (MTD)"

DRUG

Sorafenib

"Dose Escalation:~Level 1: 200 mg twice daily. Level 2: 200 mg twice daily. Level 3: 400 mg twice daily. Level 4: 400 mg twice daily.~Dose Expansion:~Maximum Tolerated Dose (MTD)"

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

All Listed Sponsors
lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT02292173 - Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer | Biotech Hunter | Biotech Hunter